探讨沙库巴曲缬沙坦对老年HFrEF患者心功能及血浆NT-proBNP、hs-TnT水平的影响  

Study the effect of sacubitril-valsartan on cardiac function、serum NT-proBNP and hs-TnT levels in elderly patients with HFrEF

作　　者：钮黎剑 卢振华 于费 何凤莲 NIU Li-jian;LU Zhen-hua;YU Fei(Department of Cardiology,Jiangsu Shengze Hospital,Nanjing Medical University,Suzhou 215228,China)

机构地区：[1]南京医科大学附属江苏盛泽医院心血管内科,江苏苏州215228

出　　处：《中国处方药》2022年第11期163-165,共3页Journal of China Prescription Drug

基　　金：苏州市吴江区临床医学专家团队引进项目(WJYJTD201704)。

摘　　要：目的探究与分析沙库巴曲缬沙坦对老年HFrEF患者心功能及血浆NT-proBNP、hs-TnT水平的影响。方法采取随机数字表法将自2019年2月~2021年2月收治的HFrEF患者120例分为两组,各60例,对照组给予醛固酮受体拮抗剂与β受体阻滞剂等常规药物治疗,观察组在对照组的治疗基础上加用沙库巴曲缬沙坦,两组均连续治疗6个月,对比两组临床疗效、心功能指标及血浆NT-proBNP、hs-TnT水平的变化,同时观察不良反应。结果与对照组相比,观察组临床总有效率较高,差异有统计学意义(P<0.05)。与对照组治疗后相比,观察组治疗后LVESD较低、LVEF较高、LVEDd较低,LVPW较高,CO及CI较高,血浆NT-proBNP水平较低、hs-TnT水平较低,差异有统计学意义(P<0.05)。两组治疗期间均未出现严重的不良反应,也没有因严重不良反而停药退出者。结论沙库巴曲缬沙坦治疗HFrEF患者可获得更好的临床疗效,促进血浆NTproBNP、hs-TnT水平改善,减缓心肌的进一步损伤,患者治疗期间无明显不良反应,安全性较高。Objective To explore and analyze the effect of sacubitril-valsartan on cardiac function and serum NT-proBNP,hs-TnT in elderly patients with HFrEF.Methods The random number table method was used to divide 120 HFrEF patients admitted in our hospital from February 2019 to February 2021into two groups,60 cases in each.The control group was treated with conventional drugs such as aldosterone receptor antagonists and beta-receptor blockers.The observation group was additionally treated with sacubitril-valsartan on the basis of the control group treatment.Both groups were treated for 6 consecutive months.The clinical efficacy,cardiac function indexes,serum NT-proBNP and hs-TnT levels were compared between the two groups,and the adverse reactions were observed.Results Compared with the control group,the total clinical effective rate of the observation group was higher,and the difference was statistically significant(P<0.05).Compared with the control group after treatment,the observation group had lower LVESd,higher LVEF,lower LVEDd,higher LVPW,higher CO and CI,lower serum NT-proBNP and lower hs-TnT levels.The difference was statistically significant(P<0.05).There were no serious adverse reactions during the treatment period in the two groups,and there was no withdrawal due to serious adverse reactions.Conclusion Sacubitril-valsartan in the treatment of HFrEF patients can achieve better clinical efficacy,promote the improvement of serum NT-proBNP and hs-TnT levels,and slow down further damage to the myocardium.There were no obvious adverse reactions during treatment,and the safety is relatively high.

关 键 词：沙库巴曲缬沙坦 左心室射血分数 心力衰竭 心功能 N末端脑利钠肽前体 超敏肌钙蛋白 

分 类 号：R541.6[医药卫生—心血管疾病]